linjc16/ctgov huggingface dataset:
Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is evaluate the outcome after posterior lamellar keratoplasty (DMEK and Ultra-thin DSAEK) for corneal transplantation.

Official Title
-----------------
Prospective Clinical Study on Postoperative Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)

Conditions
-----------------
Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy, Endothelial Dysfunction

Intervention / Treatment
-----------------
* Other: Endothelial Keratoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 18 or older Scheduled to undergo endothelial keratoplasty Able to provide written informed consent. Exclusion Criteria: Age less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Endothelial Keratoplasty<br>Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK | Other: Endothelial Keratoplasty<br> <br> * Other names: Ultra-thin DSAEK;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity (change from baseline) |  | 1, 3, 6, and 12 months and annually | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial cell density (change from baseline) |  | 1, 3, 6, and 12 months and annually | 
| Intraocular pressure (change from baseline) |  | 1, 3, 6, and 12 months and annually | 
| Manifest refraction (change from baseline) |  | 1, 3, 6, 12 months and annually | 
| corneal pachymetry (change from baseline) |  | 1, 3, 6, 12 months and annually | 
| Quality of Life, NEI-VFQ 25 (change from baseline) | Questionnaire | 3, 12 months, annualy | 
| corneal topography (change from baseline) |  | 1, 3, 6, and 12 months and annually | 
| Anterior Segment OCT of cornea and anterior chamber angle (change from baseline) |  | 1, 3, 6, and 12 months and annually | 
| postoperative Medication (change from baseline) |  | 1,3,6 and 12 months and annually | 
| Histological Sample of Recipient's Descemet Membrane | Recipient's Descemet Membrane | intraoperative |
The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage

Study Overview
=================
Brief Summary
-----------------
Women presenting to Washington Hospital Center with fetal loss would be offered participation in the study. The objective is to determine if ccffDNA obtained from maternal blood is present in the setting of missed abortion or fetal demise. The investigators primary hypothesis is that cell free fetal DNA will be present in maternal blood in the presence of a failed pregnancy.

Official Title
-----------------
The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage

Conditions
-----------------
Circulating Cell Free Fetal DNA, Intrauterine Fetal Demise, Miscarriage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women diagnosed with Intrauterine fetal demised or missed abortion Exclusion Criteria: Patients diagnosed with threatened abortion with cardiac activity present Patients with IUFD who have delivered the fetus (the induction process may already be in process, however, the fetus and placenta must be in situ at the time of blood sampling) Patients with known genetic abnormalities or mental retardation as a result of chromosomal abnormalities 13, 18, 21, or sex chromosomes. Children under the age of 18 Patients not fluent in or unable to consent to the study in English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-viable pregnancy<br>Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Presence or Absence of Cell Free Fetal DNA in Maternal Blood in the Setting of a Failed Pregnancy. | Percentage of participants with the presence of cell free fetal DNA in maternal circulation after miscarriage of intrauterine fetal demise | During initial presentation for treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Accuracy of ccffDNA Compared to Genetic Information Obtained From Amniocentesis, Chorionic Villus Sampling, Fetal, or Placental Tissue. |  | 3-4 weeks after specimen processing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Circulating cell free fetal DNA, Intrauterine fetal demise, Miscarriage
Study  COFLORES 

Study Overview
=================
Brief Summary
-----------------
Myocardial perfusion is a major parameter characterizing the status of capillary circulation of the myocardium. Its quantification is possible using Magnetic Resonance Imaging (MRI) during the 1st pass of a contrast agent through the capillary system. This technique is radiation-free, but it is difficult to repeat measurements during a single exam. Also, a number of patients suffering from cardiac disease cannot receive contrast agent injections. The investigators have developed a totally non-invasive approach for quantifying myocardial perfusion. It is based on the magnetic labeling of arterial spins. Flowing into the capillaries (Arterial spin labeling, ASL). Goal : The major goal of this research protocol is to validate a totally non-invasive method of myocardial blood flow quantification using MRI without contrast agent injection

Official Title
-----------------
Study  COFLORES :Imaging of Coronary Reserve Without Tracers

Conditions
-----------------
Myocardial Perfusion

Intervention / Treatment
-----------------
* Device: Magnetic Resonance Imaging (MRI)
* Device: phosphorus-31 Magnetic Resonance Spectroscopy
* Device: sodium-23 MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People having no heart disease or treatment referred to cardiology People having no cons -indications to MRI People having no cons -indications to gadolinium ; People not wearing implantable devices People not wearing metallic foreign bodies or risk (eg . Business of steel, etc .. ) People having no cardiovascular risk factor Person subject to the social security scheme Nobody agreeing to participate in the study and who signed the informed consent Exclusion Criteria: Refusal to go spontaneous or MRI because of claustrophobia important Trouble rhythm making MRI uninterpretable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: healthy volunteers<br> | Device: Magnetic Resonance Imaging (MRI)<br> <br> Device: phosphorus-31 Magnetic Resonance Spectroscopy<br> <br> Device: sodium-23 MRI<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myocardial perfusion | MRI based on the magnetic labeling of arterial spins | 1day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the myocardial energetic status | using phosphorus-31 Magnetic Resonance Spectroscopy | 1day | 
| the myocardial sodium | using sodium-23 MRI | 1day |
Effect of Adding Dexamethasone to Intrathecal Bupivacaine on Blood Sugar of Patients Undergoing Diabetic Foot Surgeries

Study Overview
=================
Brief Summary
-----------------
effect of intrathecal dexamethasone on blood sugar of dietetic patients

Official Title
-----------------
Effect of Adding Dexamethasone to Intrathecal Bupivacaine on Blood Sugar of Patients Undergoing Diabetic Foot Surgeries.

Conditions
-----------------
Diabetic Foot

Intervention / Treatment
-----------------
* Drug: Bupivacaine with dexamethasone
* Drug: Bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: control diabetic patients will undergo foot surgeries. Exclusion Criteria: The exclusion criteria included patient refusal, patients with major cardiac, respiratory, renal, hepatic disorders or uncontrolled diabetes mellitus, history of chronic use of analgesic medication or hypersensitivity to drugs under investigation, any contraindication to regional anesthesia, namely; patients with coagulopathy infection at puncture site, backache, spine deformity or prior surgery, neuromuscular disorders or psychic disturbances

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: group 1<br>intathecal bupivacaine | Drug: Bupivacaine<br>* bupivacaine<br>|
| Active Comparator: group 2<br>intrathecal bupivacaine with dexamethasone | Drug: Bupivacaine with dexamethasone<br>* bupivacaine with dexamethasone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood sugar |  | 24 hours |
a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions

Study Overview
=================
Brief Summary
-----------------
Magnifying endoscopy with narrow-band imaging (ME-NBI) can emphasize surface pattern and microvascular architecture of the gastric mucosa.However,the usefulness and criteria of NBI for differential diagnosis among early gastric cancers (EGC) have not been fully established.The study is based on the hypothesis: ME-NBI is useful in distinguishing EGC from other gastric lesions ME-NBI is useful in further differential diagnosis among EGCs.

Official Title
-----------------
a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions

Conditions
-----------------
Stomach Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with gastric lesions which were detected by conventional screening endoscopy and suspected of early malignancy. Exclusion Criteria: advanced gastric cancer or any other malignancy; patients under unsuitable conditions for examination or treatment, such as acute upper gastrointestinal bleeding, noncorrectable coagulopathy, severe systemic disease, etc; inability to provide informed consent; inability to provide histology of resected specimens after endoscopic treatment or surgery.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnosis accuracy of ME-NBI | ME-NBI diagnosis was made during real-time endoscopy procedure and reviewed in two weeks after ME-NBI examination. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of ME-NBI diagnosis compared with histology were measured. | in 2 weeks after ME-NBI examination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
early gastric cancer, stomach neoplasms, magnifying endoscopy, narrow band imaging
Life Experience of People Aged 60 and Over Living With HIV

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to Assess the impact of HIV on the life course of patients aged 60 and over.

Detailed Description
-----------------
COREVIH IDF Nord and CERMES3 conducted a first qualitative survey of 32 HIV patients aged 60 and over. The study, in the form of an individual interview, aimed to identify the difficulties that PLWHIV may encounter in their life course, to question their future and the impact that HIV could have. From this study, a questionnaire was drawn up covering the points raised by the qualitative study. The questionnaire was designed by doctors of the four hospitals that participated in the first study and a sociologist from CERMES3. After patient's oral agreement obtained, the study questionnaire Sociological study PVHIV ≥ 60 years will be given to the patient for completion.

Official Title
-----------------
Life Experience of People Aged 60 and Over Living With HIV: Quantitative Sociological Study

Conditions
-----------------
Virus-HIV

Intervention / Treatment
-----------------
* Other: Cohorte


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria : People aged 60 and over living with HIV and view in consultation Patient participation agreement obtained Exclusion criteria : People living with HIV less than 60 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the impact of HIV in the life cours of people aged 60 and over and the questioning of the future. | People aged 60 and over will answer to a sociological questionnaire to identify the impact of HIV in their life cours and the questioning of the future, directly or indirectly linked to HIV. | Through study completion, an average of 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VIH, Living with HIV, 60 years old and over
Implants on Mobile Health Unit

Study Overview
=================
Brief Summary
-----------------
This study explores reasons why adolescents choose to receive a nexplanon implant and remove a Nexplanon implant. Nexplanon is provided as part of the standard of care on the University of Chicago mobile health unit. This study explores reasons for implantation and removal of Nexplanon on this mobile health unit.

Official Title
-----------------
Adolescent Uptake of Implants on a Mobile Health Unit

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Device: Nexplaon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be biologically female Be seeking reproductive healthcare on a mobile health unit Be interested in receiving Nexplanon for birth control. Be between 14 and 19 years of age. Exclusion Criteria: Be biologically male Be 13 and younger or 20 and older.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nexplanon<br>This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant. | Device: Nexplaon<br>* This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.<br>|
| Removal participants<br>This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reasons for choosing Nexplanon | Information will be collected through a survey regarding why adolescents choose to receive Nexplanon. | One time, immediately before receiving implant. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reasons for choosing to remove Nexplanon | Information will be collected through a survey regarding why adolescents choose to remove Nexplanon. | One time, immediately before removing implant. |
Determination of Physical Parameters Relevant to Ophthalmic Lasers

Study Overview
=================
Brief Summary
-----------------
The use of lasers in medicine in general, and diagnosis and treatment in ophthalmology in particular, increased significantly. Making retinal surgery using lasers have become increasingly common. The goal: to diagnose eye diseases safely

Official Title
-----------------
Study of Physical Parameters Related to Laser Radiation and Its Interaction With Different Parts of the Human Eye

Conditions
-----------------
Healthy Volunteers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-40 years Refraction up to ±0.25D, General good health Written informed consent to participate in the study. Exclusion Criteria: known current ophthalmic pathology known past ophthalmic pathology (including LASIK surgery) eye glasses or contact lenses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reflected laser radiation (Watt/cm 2) | The amplitude of laser radiation reflected from the eye at different wavelengths (532nm, 800nm & 900nm) at 4 angles (-10, 05, 0 and 10 degrees ) will be measured (Watt/cm 2) | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reflection of laser radiation from the cornea (Watt/cm2) |  | 1 day | 
| Reflection of laser radiation from the retina (Watt/cm 2) |  | 1 day |
Magnetic Resonance (MR) in Asthmatic Patients

Study Overview
=================
Brief Summary
-----------------
Asthma is a disease of small airways. Affected areas have reduced lung ventilation causing reflex vasoconstriction. MR perfusion imaging of the lungs is a sensitive method of imaging zonal lung perfusion.

Detailed Description
-----------------
A cohort of 70 Asthmatic Patients and 10 controls, both sets of subjects have HRCT, MRI/A of the Thorax, and Pulmonary Function Tests to correlate the degree of pulmonary dysfunction with findings on imaging tests.

Official Title
-----------------
MR Perfusion Imaging in Asthmatic Patients

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Device: magnetic resonance imaging (MRI) of the thorax


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All asthmatic patients are eligible. Exclusion Criteria: Patients in whom MRI is contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: magnetic resonance imaging (MRI) of the thorax|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation of MR lung perfusion analysis with computed tomography (CT) findings and pulmonary function tests |  |  |